Literature DB >> 6981172

Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole.

J Spicehandler, A A Pollock, M S Simberkoff, J J Rahal.   

Abstract

Trimethoprim-sulfamethoxazole (240 mg of trimethoprim plus 1,200 mg of sulfamethoxazole) was administered intravenously in a volume of 200 ml to 7 volunteers every 12 hr for 4 days. The mean peak levels of TMP and SMZ in plasma were 3.22 and 100 micrograms/ml, respectively, on day 1 and 5.91 and 178 micrograms/ml, respectively, on day 4, when a steady state was achieved. Tests of in vitro susceptibility indicated that these concentrations are bactericidal for a large proportion of enteric gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981172     DOI: 10.1093/clinids/4.2.562

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  6 in total

1.  Another look at trimethoprim-sulfamethoxazole: its role in parenteral therapy.

Authors:  F R Sattler; J S Remington
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

Review 2.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

3.  Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.

Authors:  M N Dudley; R E Levitz; R Quintiliani; J M Hickingbotham; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

4.  Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.

Authors:  Mical Paul; Jihad Bishara; Dafna Yahav; Elad Goldberg; Ami Neuberger; Nesrin Ghanem-Zoubi; Yaakov Dickstein; William Nseir; Michael Dan; Leonard Leibovici
Journal:  BMJ       Date:  2015-05-14

5.  A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.

Authors:  Denise Türk; Nina Hanke; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2020-11-10       Impact factor: 6.321

Review 6.  Cotrimoxazole - optimal dosing in the critically ill.

Authors:  Glen R Brown
Journal:  Ann Intensive Care       Date:  2014-04-28       Impact factor: 6.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.